window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Liza

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    EMA accepts Almirall application to extend Ebglyss use in young children with atopic dermatitis

    The European Medicines Agency (EMA) has accepted Almirall’s application to [...]

    July 20, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Ten-year NHS study supports focal therapy for prostate cancer with fewer side effects

    A 10-year NHS-led study has found that focal therapy can [...]

    July 20, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Research & Development

    Mission Therapeutics signs US$292M deal for acute kidney injury programme

    Mission Therapeutics has signed a deal worth up to US$292 [...]

    July 20, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial

    Medicus Pharma has received positive feedback from FDA and central [...]

    July 20, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Compass Pathways study explores monitoring and support in COMP360 PTSD trial

    Compass Pathways has published a post hoc analysis of its [...]

    July 17, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    NEJM study provides first clinical evidence for NET-degrading therapy in lupus

    A study published in The New England Journal of Medicine [...]

    July 17, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Kairos reports positive interim Phase 1 safety data for ENV-105 in EGFR-mutated lung cancer

    Kairos Pharma has reported positive interim safety results from an [...]

    July 16, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development

    Rani reports positive Phase 1 data for oral obesity therapy RT-114

    Rani Therapeutics has reported positive initial Phase 1a data for [...]

    July 16, 2026
  • Clinical & Regulatory,Digital & Data,Genomics and sequencing,Research & Development

    Seegene launches global study to evaluate comprehensive PCR testing for respiratory infections

    Seegene has launched the Global Million Clinical Study (GMCS), an [...]

    July 16, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Compass Pathways study explores monitoring and support in COMP360 PTSD trial
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • NEJM study provides first clinical evidence for NET-degrading therapy in lupus
    Categories: Clinical & Regulatory, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • Kairos reports positive interim Phase 1 safety data for ENV-105 in EGFR-mutated lung cancer
    Categories: Clinical & Regulatory, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top